A Phase 2B, Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Trial Profile

A Phase 2B, Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2015

At a glance

  • Drugs Pramlintide (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca; Bristol-Myers Squibb
  • Most Recent Events

    • 20 Dec 2007 Status change from in progress to completed according to ClinicalTrials.gov.
    • 20 Dec 2007 The expected completion date for this trial is now 1 Jun 2007 according to ClinicalTrials.gov.
    • 21 Sep 2007 Results reported at EASD 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top